Christopher Lazarski

7PUBLICATIONS
40CO-AUTHORS
Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Gene and molecular therapyPredictive and prognostic markersBiologically active molecules
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jun 04, 2026
Tumor Microenvironmental Regulation of CAR T-Cell Therapy in High Risk Medulloblastoma.

|May 15, 2025
Autologous HIV-specific T cell therapy targeting conserved epitopes is well-tolerated in six adults with HIV: an open-label, single-arm phase 1 study.

Danielle K Sohai, Michael D Keller, Patrick J Hanley

|Apr 18, 2024
Antiviral cellular therapy for enhancing T-cell reconstitution before or after hematopoietic stem cell transplantation (ACES): a two-arm, open label phase II interventional trial of pediatric patients with risk factor assessment.

Michael D Keller, Patrick J Hanley, Yueh-Yun Chi

|Mar 30, 2024
Secondary bone marrow graft loss after third-party virus-specific T cell infusion: Case report of a rare complication.

Michael D Keller, Stefan A Schattgen, Shanmuganathan Chandrakasan

|Jun 23, 2022
OLIG2 Is a Determinant for the Relapse of MYC-Amplified Medulloblastoma.

Zhenhua Xu, Najiba Murad, Daniel Malawsky

|Nov 10, 2021
Anti-IgE effect of small-molecule-compound arctigenin on food allergy in association with a distinct transcriptome profile.

Mingzhuo Cao, Changda Liu, Kamal D Srivastava

Pageof 2

Frequent Collaborators

3 joint publications

Michael D Keller

3 joint publications

Catherine M Bollard

2 joint publications

Shanmuganathan Chandrakasan

2 joint publications

Sung-Yun Pai